2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Value, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

3433 Spatial organization of the immune bone marrow niche determines response to therapy in acute myeloid leukemia

Makayla Pardo, BA, Zeynep Kilinc2, Diana Treaba, MD3, Patrycja M Dubielecka, PhD4
1 Brown University, Providence, Rhode Island, United States
2 Brown University, Providence, Rhode Island, United States
3 Brown University, Providence, Rhode Island, United States
4 Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States

Background: Immune checkpoint inhibitors (ICI) have demonstrated limited clinical efficacy in acute myeloid leukemia (AML), despite evidence of T-cell infiltration and checkpoint receptor expression within the leukemic bone marrow. We hypothesized that chemotherapy response is determined not by T-cell exhaustion alone but by the broader spatial organization of the immune and stromal compartments within the bone marrow microenvironment.

Methods: We used Xenium (10x Genomics) spatial transcriptomics to profile matched diagnostic and post-treatment bone marrow biopsies from three responders and three non-responders who received standard 7+3 induction chemotherapy. The Human Multi-Tissue and Cancer Panel was used and expanded to include 100 custom bone marrow niche markers, reaching 477 RNA probes. Following cell segmentation and quality control, 437,694 cells from 12 samples were integrated with Harmony and clustered using Seurat. Cell types were annotated using single-cell bone marrow and AML references, along with Seurat marker based annotation. Neighborhood remodeling of stromal and immune populations was assessed from the cell type composition of each cell’s 50 nearest neighbors.

Results:  At diagnosis, both response groups exhibited abundant adaptive immune populations, including T, B, and plasma cells, and expressed immune checkpoint molecules, including HAVCR2, LAG3, CTLA4, IL2RA, and TNFRSF9. This demonstrated that failure to respond was not attributable to the absence of immune infiltration or checkpoint signaling. However, responders displayed coordinated adaptive immune program characterized by memory/helper T-cell markers (IL7R, CCR7, CD28), functional cytotoxic lymphocyte signatures (PRF1, GZMA, GZMK, FGFBP2 ), robust B-cell activation (CD19, MS4A1, CD79A, PAX5 ), and extensive plasma-cell differentiation (MZB1, JCHAIN, PRDM1, SDC1 ). In contrast, non-responders retained cytotoxic lymphocytes but exhibited greater expression of inhibitory receptors (HAVCR2, LAG3, CTLA4 ) together with a weaker humoral immune program, consistent with an activated yet less coordinated adaptive immune response. The most prominent differences at diagnosis involved monocyte/macrophage and stromal compartments. Although inflammatory FCN1?CD14? monocytes were present in both groups, non-responders were enriched for suppressive macrophage programs characterized by ARG1, VSIG4, MARCO, CD163, MRC1, APOE, and SPP1, whereas responders exhibited differentiated macrophages expressing PLA2G7, CD5L, PPARG, CFB, together with preserved antigen-presentation pathways (HLA-DRA, CD86 ). Post-treatment, responders largely preserved this coordinated immune architecture; T and plasma-cell activation persisted alongside checkpoint expression, indicating persistent immune engagement rather than immune collapse. Responders also showed greater plasma-cell representation within T-cell neighborhoods, supporting increased spatial coordination between cellular and humoral immunity. Differentiated macrophages, dendritic cell antigen-presentation programs, and regenerative stromal remodeling further supported restoration of a functional hematopoietic niche. In contrast, non-responders retained adaptive immune populations but expanded suppressive macrophage programs and progressive stromal remodeling. Thus, chemotherapy failed to eliminate the immunosuppressive monocytic/macrophage compartment or reverse stromal remodeling, leaving adaptive immune cells embedded within an environment predicted to restrict antigen presentation, cytokine support, and cytotoxic effector function.

Conclusions: AML is not primarily characterized by a deficiency of adaptive immunity or by isolated T-cell exhaustion. Instead, checkpoint molecules coexist with functional cytotoxic and humoral immune responses, particularly in patients achieving initial remission, indicating that checkpoint expression often reflects immune activation rather than reversible dysfunction. Treatment resistance is driven by persistent suppressive monocytic/macrophage populations and stromal remodeling that constrain adaptive immunity through mechanisms extending beyond PD-1/PD-L1 signaling. These findings provide a mechanistic explanation for the limited efficacy of immune checkpoint inhibition in AML and support therapeutic strategies combining checkpoint blockade with interventions targeting suppressive myeloid populations and restoration of the bone marrow microenvironment.

Makayla Pardo, BA: No relevant conflicts of interest to declare.